SomnoMed share price rises after reporting positive earnings

The SomnoMed Limited (ASX: SOM) share price has risen today after the company reported its half-year earnings.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Somnomed Limited (ASX: SOM) share price has spiked today after the sleep treatment company reported its earnings to the ASX for the six months to December 31, 2019 (1H20).

Somnomed is a medical company specialising in the treatment of patients suffering from sleep-related disorders such as obstructive sleep apnoea, which the company notes affects up to 9% of women and 25% of men globally. It has over 545,000 patients worldwide and a market capitalisation of $211 million on current prices.

SOM shares closed at $3.30 yesterday but opened at $3.33 this morning and is trending higher since, going for $3.36 at the time of writing – a rise of 2.13%. Earlier this morning, Somnomed's share price touched $3.37, which was a new 52-week high for the company. The Somnomed share price has now risen 106% in the past year.

What did SomnoMed announce today?

Pleasingly for the company, Somnomed announced a 15% increase in revenues to $33.256 million for 1H20, up from 1H19's $28.815 million.

Revenue growth was strongest in the North America region, which saw a 26% increase. European sales saw a 10% rise while the APAC (Asia Pacific, including Australia) region saw an 11% bump.

Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at $3 million, which is a 130% increase on 1H19's $1.3 million.

Compared with the previous six months (to June 30, 2019), the company has seen its Total Assets rise from $34.8 million to $42.7 million, while Total Liabilities has also increased from $16.9 million to $22.6 million – translating into Net Assets of $20.1 million (up from $17.8 million).

The company (in continuing with its policy in prior years) did not pay a dividend during the period.

Outlook for 2020

Somnomed has reiterated its guidance for FY20, for which it estimates revenues to come in the $67-$69 million range and earnings in the $6.3-$6.7 million range. There is no notice nor indication the payment of a dividend in FY20 will occur.

The company notes that it has nearly 550,000 patients and yet the global addressable market for obstructive sleep apnoea is estimated at roughly 1.36 billion people, with 54 million in the United States of America alone and a further 49 million across France and Germany.

Somnomed is hoping that this large addressable market will provide fertile ground for its new SomnoDent Avant product, which it hopes will prove to be a more comfortable and effective treatment solution for obstructive sleep apnoea.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

A good session is expected for Aussie investors today. Here's what is happening.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

These ASX shares could rise 20% to 50%

Analysts are tipping these shares to rise strongly over the next 12 months.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A view of competitors in a running event, some wearing number bibs, line up together on a starting line looking ahead as if to start a race.
Technology Shares

Here's how the ASX 200 market sectors stacked up last week

ASX technology shares led the market with a 2.48% increase last week.

Read more »

A father helps his son look through binoculars during a family holiday or day out in the city.
Opinions

Up 190% in a year, why I think Life360 shares can keep soaring higher

This tech stock has plenty of potential.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Will the RBA finally cut interest rates next week?

Let's see what economists are saying about the central bank's meeting.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »